Browse > Article

Studies for the Guidance of Safety Pharmacology Studies in Compliance with Good Laboratory Practice  

Choi Ki-Hwan (Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration)
Park Ki-Sook (Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration)
Lee Yun-Hee (Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration)
Na Hang-Kwang (Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration)
Yun Jae-Suk (Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration)
Kim Dong-Sup (Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration)
Kim Joo-Il (Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration)
Publication Information
Toxicological Research / v.22, no.2, 2006 , pp. 109-116 More about this Journal
Abstract
Safety pharmacology studies are conducted to investigated the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above. In the International Conference on Harmonisation (ICH), the guideline 'S7A: Safety Pharmacology Studies for Human Pharmaceuticals' has been developed and reached Step 5 of the ICH process in 2001. Now the Korea Food and Drug Administration (KFDA) are going to transfer 'The Guideline for General Pharmacology' into 'The Guideline for Safety Pharmacology'. Safety pharmacology studies should be performed in compliance with Good Laboratory Practice (GLP). Thus, the present paper reviews the Japanese GLP guidelines for pharmaceuticals to help the conduct and inspection of safety pharmacology studies in compliance with GLP. We also reviewed the ICH guidelines 'S7B revised : The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals' and 'E14 : The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs' to apply our drug approval systems.
Keywords
Safety pharmacology; GLP; ICH;
Citations & Related Records
연도 인용수 순위
  • Reference
1 ICH Harmonized Tripartite Guideline (1997): Timing of nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals (M3)
2 ICH Harmonized Tripartite Guideline (S7A). Safety pharmacology studies for human pharmaceuticals (2001)
3 식품의약품안전청 (2000): 비임상시험관리기준 식품의약품안전청 고시 제2000-63호 (2000. 12. 11.)
4 Cavero, I. and Crumb, W. (2005): ICH S7B draft guideline on the non-clinical strategy for testing delayed caridac repolarisation risk of drugs: a critical analysis. Expert Opin. Drug Saf., 4, 509-530   DOI   ScienceOn
5 Friedrichs, G.S., Patmore, L. and Bass, A. (2005): Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J. Pharmacol. Toxicol. Methods, 51, 6-11
6 Gallo, M.A. (2001): History and Scope of Toxicology in Casarett and Doull's Toxicology: the Basic Science of Poisons, 6th Ed (C.D. Klaassen, Ed.), McGrow-Hill, New York, pp. 3-10
7 국립독성연구원 일반약리과 (2004) : 안전성약리시험 자료집 III - ICH Guidelines for Safety Pharmacology Study
8 국립독성연구원 일반약리과 (2004) : 안전성약리시험 자료집 IV - 안전성약리시험에 대한 일본의약품 GLP평가 자료집
9 ICH Harmonized Tripartite Guideline (2005). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14)
10 Choi, K.H., Park, I.S., Lim, H.K., Oh, W.Y., Wang, S.Y., Kim, S.H., Kim, J.I. and Kim, D.S. (2003): Drug development and guideline for safety pharmacology studies. Yakhak Hoeji, 47, 104-109
11 국립독성연구원 일반약리과 (2004): 안전성약리시험 자료집 I - IQPC Safety Pharmacology Conference & Workshop
12 Valentin, J.P., Bass, A.S., Atrakchi, A., Olejniczak, K. and Kannosuke, F. (2005): Challenges and lessons learned since implementation of the safety. J. Pharmacol. Toxicol. Methods, 52, 22-29   DOI   ScienceOn
13 ICH Harmonized Tripartite Guideline (2005). The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B)
14 Paakkari, I. (2002): Cardiotoxicity of new antihistamines and cisapride. Toxicol. Lett., 127, 279-284   DOI   ScienceOn
15 일본 의약품 GLP Q&A집 편집위원회 (2003): 의약품 GLP Q&A집
16 국립독성연구원 일반약리과 (2004) : 안전성약리시험 자료집 II - Safety Pharmacology Society 4th Annual Meeting
17 일본후생노동성 (Japanese Ministry of Health, Labor and Welfare) (2001): 安全性藥理試驗 가이드라인 藥審發 第 902 (2001. 6. 21.)
18 ICH Harmonized Tripartite Guideline (1997): Preclinical safety evaluation of biotechnology-derived pharmaceuticals (M6)
19 (재)일본약제사연수센타 (2004): 의약품 GLP 가이드라인
20 Shah, R.R. (2005): Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead. Drug Saf., 28, 1009-1028   DOI   ScienceOn
21 식품의약품안전청 (1998): 의약품 등의 일반약리시험 지침 식품의 약품안전청고시 제1998-62호 (1998. 5. 29)